Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials.

about

Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials.

Item

http://www.wikidata.org/entity/Q38614152

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Assessing the relationship bet ...... tic review of clinical trials.

@en

type

Item

label

Assessing the relationship bet ...... tic review of clinical trials.

@en

prefLabel

Assessing the relationship bet ...... tic review of clinical trials.

@en

P1476

Assessing the relationship bet ...... atic review of clinical trials

@en

P2093

Alessandro Conti

http://www.w3.org/2001/XMLSchema#string

Francesca Tartari

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Cluster analysis and display of genome-wide expression patterns

Improving clustering by imposing network information.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

P304

e0183639

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0183639

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Roy Cerqueti

P5008

ScienceSource

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28829823

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

biomedical investigative technique

P932

5567914

http://www.w3.org/2001/XMLSchema#string